<DOC>
	<DOCNO>NCT00216372</DOCNO>
	<brief_summary>The purpose study determine whether lanreotide 30mg microparticles effective relief clinical symptom due small bowel obstruction inoperable patient peritoneal carcinomatosis .</brief_summary>
	<brief_title>Efficacy Safety Lanreotide Microparticles Palliative Treatment Peritoneal Carcinomatosis</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Intestinal Obstruction</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>digestive obstruction locate upper part gastrointestinal tract digestive obstruction malignant origin peritoneal carcinomatosis confirm CT Scan least two vomit episode per day presence nasogastric suction tube inoperable patient specific anticancer therapy within previous 15 day sign bowel perforation somatostatin analogue treatment bowel obstruction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>carcinomatosis</keyword>
</DOC>